Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 3363  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (68 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed6080    
    Printed119    
    Emailed3    
    PDF Downloaded281    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2005  |  Volume : 53  |  Issue : 2  |  Page : 243

Preventive therapy of migraine


Department of Neurological Sciences, Apollo Hospitals, Hyderabad, India

Date of Acceptance10-Apr-2005

Correspondence Address:
Sudhir Kumar
Department of Neurological Sciences, Apollo Hospitals, Hyderabad
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 16010078

Rights and PermissionsRights and Permissions



How to cite this article:
Kumar S. Preventive therapy of migraine. Neurol India 2005;53:243

How to cite this URL:
Kumar S. Preventive therapy of migraine. Neurol India [serial online] 2005 [cited 2019 Sep 22];53:243. Available from: http://www.neurologyindia.com/text.asp?2005/53/2/243/16429


Sir,

I read with interest the recent report of acute myopia induced by topiramate used for migraine prophylaxis.[1] I would like to make certain observations.

Firstly, Bhattacharyya et al used two medications (flunarizine and topiramate) as the initial preventive treatment of migraine. However, the guidelines recommend usage of a single drug. The drug should be considered a failure only after an adequate trial (2-3 months) has been given.[2] After the failure of the first drug, one has the option of using another drug or a two-drug combination. Also, Bhattacharyya et al have used two second-line agents for migraine prevention at the onset. However, guidelines recommend using a first-line agent initially, which include propranolol, divalproex sodium, sodium valproate and amitryptiline among others.[2],[3] Considering the fact that adverse effects are common with most of the drugs used for migraine prevention, one should be cautious in starting two second-line drugs as the first step.

Secondly, the choice of agent should also be individualized depending on the patient profile. Bhattacharyya et al started flunarizine in an obese patient (on sibutramine for the same). Weight gain as a side effect of flunarizine is well known.[4]



 
  References Top

1.Bhattacharyya KB, Basu S. Acute myopia induced by topiramate: Report of a case and review of the literature. Neurol India 2005;53:108-109.  Back to cited text no. 1    
2.Snow V, Weiss K, Wall EM, Mottur-Pilson C; American Academy of Family Physicians; American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002;137:840-9.  Back to cited text no. 2    
3.Geraud G, Lanteri-Minet M, Lucas C, Valade D; French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305-18.  Back to cited text no. 3    
4.Thomas M, Behari M, Ahuja GK. Flunarizine in migraine prophylaxis: an Indian trial. Headache 1991;31:613-5.  Back to cited text no. 4    




 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow